Dembélé S B, Diakité I, Samaké M, Coulibaly B, Saye Z, Bah A, Konaté S, Togo E, Sidibé B Y, Coulibaly Z, Kanté L, Togo A
Service de chirurgie générale CHU Gabriel Touré.
Service Anatomie pathologie CHU Point G.
Mali Med. 2019;34(2):36-39.
Breast cancer is the second cancer of women in Mali. Immunohistochemistry is poorly performed in our African countries.
To describe the immunohistochemical aspect and determine the prognosis of breast cancer.
This is a retrospective descriptive study (March 2006-July 2016) in the General Surgery Department of Gabriel Toure University Hospital in Bamako, Mali. Immunohistochemistry was performed in all patients through a collaboration of our German partners.
We collected 98 patients (95 women and 3 men) with an average age of 40.04 ± 13.07 years. Twenty-two patients (22.44%) had a personal history of benign breast disease. In 16 patients (16.33%), we found a family breast cancer. The most common histological types were intra ductal carcinoma with 84 (85.72%) and invasive lobular carcinoma in 9 cases (9.18%). Immunohistochemistry found a predominance of triple negative with forty nine patients (50%) followed by Luminal A subtype with 26 cases (26.23%). According to the TNM classification, 44 patients (44.90%) were received at stage III. The median survival was 60 months in the group of patients who received hormone therapy versus 28 months for the group without hormone therapy (p = 0.007).
Immunohistochemistry is essential for the adequate management of breast cancer. Its realization has allowed us to improve the prognosis of hormone-dependent cancers.
乳腺癌是马里女性的第二大癌症。免疫组织化学在我们这些非洲国家开展得很差。
描述乳腺癌的免疫组织化学特征并确定其预后。
这是一项回顾性描述性研究(2006年3月至2016年7月),在马里巴马科的加布里埃尔·图雷大学医院普通外科进行。通过与我们德国合作伙伴的合作,对所有患者进行了免疫组织化学检测。
我们收集了98例患者(95名女性和3名男性),平均年龄为40.04±13.07岁。22例患者(22.44%)有乳腺良性疾病个人史。16例患者(16.33%)有家族性乳腺癌。最常见的组织学类型是导管内癌,共84例(85.72%),浸润性小叶癌9例(9.18%)。免疫组织化学发现三阴性占主导,有四十九例患者(50%),其次是Luminal A亚型,有26例(26.23%)。根据TNM分类,44例患者(44.90%)就诊时为III期。接受激素治疗的患者组中位生存期为60个月,未接受激素治疗的患者组为28个月(p = 0.007)。
免疫组织化学对于乳腺癌的恰当管理至关重要。其实施使我们能够改善激素依赖性癌症的预后。